Dorato Capital Management Buys New Position in Amgen Inc. $AMGN

Dorato Capital Management bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 4,799 shares of the medical research company’s stock, valued at approximately $1,579,000. Amgen comprises approximately 1.2% of Dorato Capital Management’s holdings, making the stock its 21st largest position.

Several other institutional investors have also added to or reduced their stakes in the business. Capital World Investors grew its position in shares of Amgen by 11.5% during the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after acquiring an additional 1,935,876 shares during the period. National Bank of Canada FI raised its stake in shares of Amgen by 237.7% in the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock worth $346,076,000 after buying an additional 863,216 shares during the period. Van ECK Associates Corp lifted its position in shares of Amgen by 71.8% during the 3rd quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company’s stock valued at $383,254,000 after buying an additional 567,400 shares in the last quarter. Amundi grew its stake in shares of Amgen by 19.5% during the 2nd quarter. Amundi now owns 2,303,169 shares of the medical research company’s stock valued at $683,696,000 after acquiring an additional 376,228 shares during the period. Finally, Fisher Asset Management LLC grew its stake in shares of Amgen by 91.6% during the 3rd quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company’s stock valued at $221,607,000 after acquiring an additional 375,463 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Cantor Fitzgerald raised their target price on shares of Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Citigroup increased their price objective on shares of Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Freedom Capital downgraded shares of Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. Jefferies Financial Group assumed coverage on shares of Amgen in a research note on Tuesday, March 10th. They set a “hold” rating and a $350.00 target price on the stock. Finally, Oppenheimer set a $400.00 target price on shares of Amgen and gave the stock an “outperform” rating in a report on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $354.60.

Amgen Price Performance

AMGN stock opened at $347.94 on Friday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The company’s fifty day moving average price is $363.59 and its 200-day moving average price is $331.85. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The company has a market capitalization of $187.56 billion, a PE ratio of 24.45, a price-to-earnings-growth ratio of 3.50 and a beta of 0.47.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen’s quarterly revenue was up 8.6% on a year-over-year basis. During the same period last year, the company posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. Amgen’s payout ratio is presently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.